OTCMKTS:LBTSF

Almirall - LBTSF Stock Forecast, Price & News

$9.28

0.00 (0.00%)

(As of 11/29/2022 12:00 AM ET)

Add

Compare

Today's Range: $9.28
▼
$9.28
50-Day Range: $9.28
▼
$9.28
52-Week Range: $9.28
▼
$9.28

Volume: N/A
Average Volume: 383 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.50

About Almirall (OTCMKTS:LBTSF) Stock

Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications, as well as for cardiovascular, musculo-skeletal, respiratory, and nervous system; alimentary tract and metabolism; antiinfectives for systemic use; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. Its products include Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor, and Efficib/Tesavel. Almirall, S.A. has collaboration and partnership agreements with Tyris Therapeutics, BIOMAP, the University of Dundee, Kaken Pharmaceutical Co Ltd., Ichnos Sciences Inc., the University Carlos III Madrid and MEDINA Foundation, 23andMe, Inc., HitGen Ltd., WuXi Biologics, Eli Lilly and Company, and Athenex, Inc. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.

Receive LBTSF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Almirall and its competitors with MarketBeat's FREE daily newsletter.

LBTSF Stock News Headlines

November 10, 2022 | msn.com

Spain's Almirall Q3 core earnings fall 13%; keeps outlook

October 3, 2022 | seekingalpha.com

Week In Review: YishengBio To List On Nasdaq Via SPAC Merger At An $834 Million Value

September 29, 2022 | benzinga.com

Simcere and Almirall Enter into a Licensing Agreement for IL-2 mu-Fc

August 18, 2022 | finance.yahoo.com

Almirall's Klisyri® (tirbanibulin) receives strong recommendation in American Academy of Dermatology AK guideline update

July 26, 2022 | seekingalpha.com

Almirall, S.A. 2022 Q2 - Results - Earnings Call Presentation

July 25, 2022 | seekingalpha.com

Almirall, S.A. (LBTSF) CEO Gianfranco Nazzi on Q2 2022 Results - Earnings Call Transcript

July 25, 2022 | msn.com

Spain's Almirall returns to profitability in first half as sales grow

June 13, 2022 | finance.yahoo.com

Happify Health and Almirall Go Live with Digital Solution to Support Psoriasis Patients

June 7, 2022 | finanznachrichten.de

Almirall, S.A.: Almirall: Eight out of Ten Patients Maintained Skin Clearance at One Year in Lebrikizumab Atopic Dermatitis Monotherapy Trials

June 7, 2022 | finance.yahoo.com

Almirall: Eight out of Ten Patients Maintained Skin Clearance at One Year in Lebrikizumab Atopic Dermatitis Monotherapy Trials

May 19, 2022 | seekingalpha.com

Evotec, Almirall team up to discover therapies for skin diseases

May 19, 2022 | finanznachrichten.de

Evotec AG: Evotec and Almirall Enter into a Multi-Target Alliance in Medical Dermatology

May 19, 2022 | markets.businessinsider.com

DGAP-News: Evotec and Almirall enter into a multi-target alliance in medical dermatology

May 19, 2022 | nasdaq.com

Evotec Announces Collaboration With Almirall

May 9, 2022 | seekingalpha.com

Almirall, S.A. (LBTSF) CEO Gianfranco Nazzi on Q1 2022 Results - Earnings Call Transcript

May 9, 2022 | nasdaq.com

Spain's Almirall confirms 2022 target after first quarter profit drop

May 9, 2022 | seekingalpha.com

Almirall, S.A. reports Q1 results

May 8, 2022 | markets.businessinsider.com

Here's what Wall Street expects from Almirall's earnings

May 4, 2022 | finance.yahoo.com

Almirall Deploys Aktana's Contextual Intelligence 360 to Optimize Customer Engagement

April 11, 2022 | finanznachrichten.de

Almirall, S.A.: Almirall: Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis

April 11, 2022 | finance.yahoo.com

Almirall: Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis

March 26, 2022 | finanznachrichten.de

Almirall, S.A.: Almirall: Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Pivotal Phase 3 Atopic Dermatitis Studies

February 22, 2022 | seekingalpha.com

Almirall reports FY results

February 21, 2022 | nasdaq.com

Spain's Almirall swings to FY loss, announces leadership change

February 21, 2022 | nasdaq.com

Almirall Posts Net Loss In FY21, Core EBITDA Up; Sees Weak EBITDA, Core Net Sales Growth In FY22

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive LBTSF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Almirall and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:LBTSF
CUSIP: N/A
CIK: N/A
Web: www.almirall.com
Phone: 34 93 291 30 00
Fax: N/A
Employees: 1,786
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $11.50
High Stock Price Forecast: $13.00
Low Stock Price Forecast: $10.00
Forecasted Upside/Downside: +23.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Key Executives

Mr. Gianfranco Nazzi (Age 53)
CEO & Exec. Director

Mr. Michael McClellan (Age 50)
Exec. VP of Fin., CFO & Member of Management Board

Mr. Joan Figueras Carreras
Vice Sec., Member of Mgmt. Board, Non-Voting Director & Exec. Director of Corp. Governance

Mr. Eloi Crespo Cervera
Sr. VP of Industrial Operations & Member of Management Board

Mr. Jordi Sabé Richer
Sr. VP of Corp. Devel. & Member of Management Board

Mr. Esteve Conesa Panicot
Sr. VP of HR & Member of Management Board

Dr. Volker Koscielny
Chief Medical Officer & Member of Management Board

Mr. Pablo Alvarez
Member of Management Board, Pres of Almirall US & GM of Almirall US

Dr. Karl Ziegelbauer
Exec. VP of R&D, CSO and Member of Management Board

Mr. Paolo Cionini
Chief Commercial Officer Europe & International and Member of Management Board

Key Competitors

View All Competitors

LBTSF Stock - Frequently Asked Questions

Should I buy or sell Almirall stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Almirall in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LBTSF shares.
View LBTSF analyst ratings or view top-rated stocks.
What is Almirall's stock price forecast for 2023?: 4 Wall Street research analysts have issued 12-month price targets for Almirall's stock. Their LBTSF share price forecasts range from $10.00 to $13.00. On average, they expect the company's share price to reach $11.50 in the next twelve months. This suggests a possible upside of 23.9% from the stock's current price.
View analysts price targets for LBTSF or view top-rated stocks among Wall Street analysts.
How have LBTSF shares performed in 2022?: Almirall's stock was trading at $12.10 on January 1st, 2022. Since then, LBTSF shares have decreased by 23.3% and is now trading at $9.28.
View the best growth stocks for 2022 here.
Are investors shorting Almirall?: Almirall saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 338,200 shares, an increase of 16.3% from the October 31st total of 290,800 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is currently ∞ days.
View Almirall's Short Interest.

What is Almirall's stock symbol?: Almirall trades on the OTCMKTS under the ticker symbol "LBTSF."
How do I buy shares of Almirall?: Shares of LBTSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Almirall's stock price today?: One share of LBTSF stock can currently be purchased for approximately $9.28.
How many employees does Almirall have?: The company employs 1,786 workers across the globe.
How can I contact Almirall?: Almirall's mailing address is Ronda General Mitre, 151, Barcelona, Catalonia 08022. The official website for the company is www.almirall.com. The company can be reached via phone at 34 93 291 30 00.

This page (OTCMKTS:LBTSF) was last updated on 11/30/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial